文献速递淋巴瘤

GADOLIN研究:利妥昔单抗难治性惰性非霍奇金淋巴瘤患者接受奥妥珠单抗联合苯达莫司汀诱导及奥妥珠单抗维持治疗的总生存获益

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
PubMed 文献 · J Clin Oncol · 2018-03-27

GADOLIN随机III期试验更新分析纳入413例利妥昔单抗难治性惰性非霍奇金淋巴瘤患者,比较奥妥珠单抗联合苯达莫司汀(G-B)与苯达莫司汀单药。中位随访31.8个月,G-B组中位无进展生存期25.8个月 vs 苯达莫司汀单药组14.1个月(HR 0.57,95%CI 0.44-0.73,P<.001),总生存亦延长(HR 0.67,95%CI 0.47-0.96,P=.027)。

要点

  • G-B组中位无进展生存期25.8个月,苯达莫司汀单药组14.1个月,HR 0.57(95%CI 0.44-0.73,P<.001)。
  • 总生存HR 0.67(95%CI 0.47-0.96,P=.027),滤泡性淋巴瘤亚组获益相似。
  • 3-5级不良事件发生率G-B组72.5% vs 苯达莫司汀单药组65.5%,两组毒性相似。

核心结论

  • 更新分析证实G-B方案较苯达莫司汀单药改善无进展生存期,并在意向治疗人群和滤泡性淋巴瘤患者中显示总生存获益,两组毒性相似。

研究设计与样本

  • 随机III期GADOLIN试验的更新分析,纳入413例组织学确诊的利妥昔单抗难治性CD20+惰性非霍奇金淋巴瘤患者,意向治疗组G-B 204例、苯达莫司汀单药209例;335例为滤泡性淋巴瘤(G-B 164例、苯达莫司汀单药171例)。

主要发现

  • 中位随访31.8个月,意向治疗人群中位无进展生存期G-B组25.8个月 vs 苯达莫司汀单药组14.1个月(HR 0.57,95%CI 0.44-0.73,P<.001)。
  • 总生存亦延长(HR 0.67,95%CI 0.47-0.96,P=.027),滤泡性淋巴瘤患者无进展生存期和总生存获益相似。
  • 3-5级不良事件发生率G-B组148例(72.5%) vs 苯达莫司汀单药组133例(65.5%),最常见中性粒细胞减少(G-B 34.8% vs 苯达莫司汀单药27.1%)、血小板减少(10.8% vs 15.8%)、贫血(7.4% vs 10.8%)和输注相关反应(9.3% vs 3.4%)。
  • 严重不良事件G-B组89例(43.6%) vs 苯达莫司汀单药组75例(36.9%);致死性不良事件分别为16例(7.8%)和13例(6.4%)。

关键数值与推荐

  • G-B方案:奥妥珠单抗1000 mg(第1周期第1、8、15天;第2-6周期第1天)联合苯达莫司汀90 mg/m2/天(所有周期第1、2天)。
  • 苯达莫司汀单药方案:120 mg/m2/天。
  • 未出现疾病进展的G-B组患者接受奥妥珠单抗维持治疗1000 mg每2个月一次,最长2年。

临床怎么用

  • 原文结论为更新分析证实G-B方案的无进展生存期获益并显示总生存获益,毒性相似,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated with obinutuzumab (GA101; G) and bendamustine (B). Patients and Methods Patients with histologically documented, rituximab-refractory CD20+ indolent non-Hodgkin lymphoma received G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2/d (days 1 and 2, all cycles) or B 120 mg/m2/d monotherapy. Patients who did not experience disease progression with G-B received G maintenance (1,000 mg every 2 months) for up to 2 years. The primary end point was progression-free survival (PFS). Results Of 413 randomly assigned patients (intention-to-treat [ITT]: G-B, n = 204; B monotherapy, n = 209), 335 had follicular lymphoma (FL; G-B, n = 164; B monotherapy, n = 171). After a median follow-up of 31.8 months, median PFS in ITT patients was 25.8 months (G-B) and 14.1 months (B monotherapy; hazard ratio [HR], 0.57; 95% CI, 0.44 to 0.73; P < .001). Overall survival (OS) also was prolonged (HR, 0.67; 95% CI, 0.47 to 0.96; P = .027). PFS and OS benefits were similar in patients with FL. Grade 3 to 5 adverse events (AEs) were reported by 148 (72.5%) and 133 (65.5%) patients in the G-B and B monotherapy arms, respectively, most commonly neutropenia (G-B, 34.8%; B monotherapy, 27.1%), thrombocytopenia (10.8% and 15.8%), anemia (7.4% and 10.8%), and infusion-related reactions (9.3% and 3.4%). Serious AEs occurred in 89 G-B patients (43.6%) and 75 B monotherapy patients (36.9%); fatal AEs occurred in 16 (7.8%) and 13 (6.4%), respectively. Conclusion This updated analysis confirms the PFS benefit for G-B shown in the primary analysis. A substantial OS benefit also was demonstrated in the ITT population and in patients with FL. Toxicity was similar for both treatments.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cheson BD, Chua N, Mayer J, et al. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018. PMID: 29584548. doi:10.1200/JCO.2017.76.3656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。